Медицинские вопросы и проблемы подростков, больных муковисцидозом. Коллектив авторов
Чтение книги онлайн.
Читать онлайн книгу Медицинские вопросы и проблемы подростков, больных муковисцидозом - Коллектив авторов страница 21
![Медицинские вопросы и проблемы подростков, больных муковисцидозом - Коллектив авторов Медицинские вопросы и проблемы подростков, больных муковисцидозом - Коллектив авторов](/cover_pre303404.jpg)
Kristidis P Bozon D, Corey M et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992;50:1178-84
85
The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. New Engl J Med 1993; 329:1308-13
86
McKone EF, Emerson SS, Edwards KL et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361:1671-6
87
McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130:1441-7
88
Sanders DB, Hoffman LR, Emerson J et al. Return of FEV(1) after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-34
89
Wagener JS, VanDevanter DR, Pasta DJ, Regelmann W, Morgan WJ, Konstan MW. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2012. (In press) DOI: 10.1002/ ppul. 22652
90
Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9
91
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54
92
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
93
Dziuban EJ, Saab-Abazeed L, Chaudhry SR, Streetman DS, Nasr SZ. Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol 2010; 45:450-8
94
Modi AC, Marciel KK, Slater SK, Drotar D, Quittner AQ. The influence of parental supervision on medical adherence in adolescents with cystic fibrosis: developmental shifts from pre to late adolescence. Children's Health Care 2008; 37:78-92
95
Vandenbranden SL, McMullen A, Schechter MS et al. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol 2012;47:135-43
96
Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-54
97
Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151:249-54
98
Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007;176:1084-9
99
Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ. The initiation of inhaled corticosteroid therapy in cystic fibrosis patients is associated with a slower rate of lung function decline. J Pediatr 2008; 153:746-51
100
Konstan MW, Wagener JS, Pasta DJ et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011;46:545-53
101
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54
102
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
103
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72
104
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54
105
Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012; 129:348-55
106
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-34
107
Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15:75-88
108
Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-87
109
Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012; 129:348-55
110
VanDevanter DR, Rasouliyan LH, Murphy TM et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43:739-44
111
Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the